Hemorrhagic Shock - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 38 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hemorrhagic Shock - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Hemorrhagic Shock - Pipeline Review, H2 2016', provides an overview of the Hemorrhagic Shock pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Hemorrhagic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemorrhagic Shock and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hemorrhagic Shock
- The report reviews pipeline therapeutics for Hemorrhagic Shock by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Hemorrhagic Shock therapeutics and enlists all their major and minor projects
- The report assesses Hemorrhagic Shock therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hemorrhagic Shock

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hemorrhagic Shock
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hemorrhagic Shock pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hemorrhagic Shock Overview 6
Therapeutics Development 7
Pipeline Products for Hemorrhagic Shock - Overview 7
Pipeline Products for Hemorrhagic Shock - Comparative Analysis 8
Hemorrhagic Shock - Therapeutics under Development by Companies 9
Hemorrhagic Shock - Therapeutics under Investigation by Universities/Institutes 10
Hemorrhagic Shock - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hemorrhagic Shock - Products under Development by Companies 13
Hemorrhagic Shock - Products under Investigation by Universities/Institutes 14
Hemorrhagic Shock - Companies Involved in Therapeutics Development 15
Biomedica Management Corporation 15
Leading BioSciences, Inc. 16
NuvOx Pharma LLC 17
Hemorrhagic Shock - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
AM/AMBP-1 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
LB-1148 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Neutrolide - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
NVX-408 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Synthetic Peptide to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis and Hemorrhagic Shock - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
YW-356 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Hemorrhagic Shock - Dormant Projects 35
Hemorrhagic Shock - Discontinued Products 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38

List of Tables

Number of Products under Development for Hemorrhagic Shock, H2 2016 7
Number of Products under Development for Hemorrhagic Shock - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Hemorrhagic Shock - Pipeline by Biomedica Management Corporation, H2 2016 15
Hemorrhagic Shock - Pipeline by Leading BioSciences, Inc., H2 2016 16
Hemorrhagic Shock - Pipeline by NuvOx Pharma LLC, H2 2016 17
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Stage and Target, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Hemorrhagic Shock - Dormant Projects, H2 2016 35
Hemorrhagic Shock - Discontinued Products, H2 2016 36